Alpha 2.0
Login Register
» Authors » Jean Pierre Vannier

Jean Pierre Vannier

Explore the profile of Jean Pierre Vannier including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 234
Followers 0
Related Specialties
Hematology
Pediatrics
General Medicine
Top 10 Co-Authors
Benedicte Neven
Patrick Lutz
Jean-Hugues Dalle
Mathieu Kuentz
Eliane Gluckman
Josu de la Fuente
Gerard Michel
Alina Ferster
Belinda Pinto Simoes
Annalisa Ruggeri
Published In
Thromb Haemost
Orphanet J Rare Dis
Pediatr Blood Cancer
Hum Gene Ther
Blood
Affiliations
Soon will be listed here.
Recent Articles
1.
New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning
Poinsignon V, Faivre L, Nguyen L, Neven B, Broutin S, Moshous D, et al.
Pediatr Blood Cancer . 2020 Jul; 67(10):e28603. PMID: 32706505
Background: Busulfan (Bu) is the cornerstone of conditioning regimens prior to hematopoietic stem cell transplantation, widely used in both adults and children for the treatment of malignant and nonmalignant diseases....
2.
Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease
Cappelli B, Volt F, Tozatto-Maio K, Scigliuolo G, Ferster A, Dupont S, et al.
Haematologica . 2019 Apr; 104(12):e543-e546. PMID: 31018975
No abstract available.
3.
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation
Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al.
Blood . 2016 Dec; 129(11):1548-1556. PMID: 27965196
Despite advances in supportive therapy to prevent complications of sickle cell disease (SCD), access to care is not universal. Hematopoietic cell transplantation is, to date, the only curative therapy for...
4.
Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French Severe Congenital Neutropenia Registry
Desplantes C, Fremond M, Beaupain B, Harousseau J, Buzyn A, Pellier I, et al.
Orphanet J Rare Dis . 2014 Dec; 9:183. PMID: 25491320
Background: The purpose of this study was to describe the natural history of severe congenital neutropenia (SCN) in 14 patients with G6PC3 mutations and enrolled in the French SCN registry....
5.
Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation
Couronne L, Schneider P, Picquenot J, Laberge S, Bastard C, Vannier J
J Pediatr Hematol Oncol . 2009 Jan; 30(12):959-62. PMID: 19131792
According to biologic features, there is a substantial "gray zone" between nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs) (Poppema lymphomas) and T-cell/histiocyte-rich B-cell lymphomas (T/HRBCLs). Transformation from an NLPHL to a...
6.
Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway
Li H, Soria C, Griscelli F, Opolon P, Soria J, Yeh P, et al.
Hum Gene Ther . 2005 Oct; 16(10):1157-67. PMID: 16218777
The urokinase plasminogen activator (uPA) is implicated in both cancer cell invasion and angiogenesis. It can interact with a specific receptor (uPAR) via the epidermal growth factor (EGF)-like domain in...
7.
Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase
Vincent L, Albanese P, Bompais H, Uzan G, Vannier J, Steg P, et al.
Thromb Haemost . 2003 Mar; 89(3):530-7. PMID: 12624638
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduce the risk of coronary event by cholesterollowering dependent and independent mechanisms. We have already described that the inhibitory effect of cerivastatin on angiogenesis...